

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

L1 30772 SEA SUPPLEMENT  
L2 30 SEA L1 AND NITRIC OXIDE PRODUCTION  
L3 0 SEA L2 AND SAPONINS  
L4 0 SEA L2 AND GENSING  
L5 25 SEA L2 AND L(W)ARGININE  
L6 1 SEA L2 AND N(W)ACETYL(W)CYSTEINE  
DISPLAY BROWSE  
L7 1 SEA L2 AND FOLIC ACID  
DISPLAY BROWSE

FILE 'CAPLUS' ENTERED AT 17:20:40 ON 03 APR 2000

L8 1039 SEA NITRIC OXIDE PRODUCTION  
L9 2 SEA L8 AND FOLIC ACID  
DISPLAY BROWSE

L1 30772 SEA SUPPLEMENT  
L2 30 SEA L1 AND NITRIC OXIDE PRODUCTION  
L3 0 SEA L2 AND SAPONINS  
L4 0 SEA L2 AND GENSING  
L5 25 SEA L2 AND L(W) ARGININE  
L6 1 SEA L2 AND N(W) ACETYL(W) CYSTEINE  
DISPLAY BROWSE  
L7 1 SEA L2 AND FOLIC ACID  
DISPLAY BROWSE

EXF 514/45; 514/565  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L7 ANSWER 1 OF 1 USPATFULL

SUMM Endogenous **nitric oxide production** can  
also increase blood flow by reducing the number of blood elements  
adhering to the lumen of the vessel. In. . .

SUMM Examples of vitamins suitable for incorporation into the medicament of  
the invention include Vitamin A, Vitamin D, Vitamin K, **folic**  
**acid**, thiamin, riboflavin, Vitamin B.sub.6, Vitamin B.sub.12,  
niacin, biotin and panthotenic acid in pharmaceutically acceptable  
form.

SUMM The medicament or formulation is primarily intended for use as a  
dietary

**supplement**. In such a case, the amount of energy supplied by it  
should not be too excessive, in order not to unnecessarily suppress the  
patients appetite. The **supplement** should conveniently comprise  
energy sources in an amount supplying from 600 to 1500 Kcal/day. The  
contribution of the nitrogen source, . . .

DETD . . . diet 0.10

Zinc mg/kg diet 12.00

The vitamin mixture comprises per kg diet:

A.sup.(1) 4000.00 IU

D.sup.(2) 1000.00 IU

E.sup.(3) 30.00 IU

K.sub.1 50.00 .mu.g

Choline 1000.00 mg

**Folic acid** 1.00 mg

Niacin 20.00 mg

Pantothenate (calcium)  
8.00 mg

Riboflavin 3.00 mg

Thiamin 4.00 mg

Vitamin B.sub.6 6.00 mg

Vitamin B.sub.12 50.00 .mu.g

---

.sup.(1) Vitamin A: . . .

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:fi8ull

'FI8ULL' IS NOT VALID HERE

If you enter "BRIEF", you will see a short review of your session  
history. If you enter "FULL", you will see a complete review of your  
session history.

ENTER (BRIEF) OR FULL:display his

'DISPLAY HIS' IS NOT VALID HERE

If you enter "BRIEF", you will see a short review of your session  
history. If you enter "FULL", you will see a complete review of your  
session history.

ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)  
REVISED CLASS FIELDS (L) LAST RELOADED: Oct 1999  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: NOV 1999

>>> Page images are available for patents from 1/1/96. Current <<<  
>>> week patent text is typically loaded by Thursday morning and <<<  
>>> page images are available for display by the end of the day. <<<  
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<  
>>> is included in file records. A thesaurus is available for the <<<  
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<  
>>> fields. This thesaurus includes catchword terms from the <<<  
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<  
>>> available for the WIPO International Patent Classification <<<  
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<  
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<  
>>> the /IC5 and /IC fields include the corresponding catchword <<<  
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s supplement

L1 30772 SUPPLEMENT

=> s L1 and nitric oxide production

49710 NITRIC  
348134 OXIDE  
532819 PRODUCTION  
207 NITRIC OXIDE PRODUCTION  
(NITRIC(W)OXIDE(W)PRODUCTION)

L2 30 L1 AND NITRIC OXIDE PRODUCTION

=> s L2 and saponins

1085 SAPONINS  
L3 0 L2 AND SAPONINS

=> s L2 and gensing

2 GENSING  
L4 0 L2 AND GENSING

=> s L2 and l(w)arginine

611177 L  
19592 ARGININE  
3493 L(W)ARGININE  
L5 25 L2 AND L(W)ARGININE

=> s L2 and N(w)acetyl(w)cysteine

773027 N  
66709 ACETYL  
17143 CYSTEINE  
398 N(W)ACETYL(W)CYSTEINE  
L6 1 L2 AND N(W)ACETYL(W)CYSTEINE

=> display browse

ENTER (L6) OR L#:L6

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL  
AN 1999:43208 USPATFULL  
TI Enhancement of vascular function by modulation of endogenous  
**nitric oxide production** or activity  
IN Cooke, John P., Palo Alto, CA, United States  
Dzau, Victor J., Los Altos Hills, CA, United States  
Gibbons, Gary H., Palo Alto, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 5891459 19990406  
AI US 1995-556035 19951109 (8)  
RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-76312,  
filed on 11 Jun 1993, now patented, Pat. No. US 5428070  
DT Utility  
LN.CNT 1730  
INCL INCLM: 424/439.000  
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
NCL NCLM: 424/439.000  
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
IC [6]  
ICM: A23L001-305  
ICS: A61K009-00; A61K031-195  
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;  
514/564; 514/565; 424/439; 424/441  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL  
AN 1999:43208 USPATFULL  
TI Enhancement of vascular function by modulation of endogenous  
**nitric oxide production** or activity  
IN Cooke, John P., Palo Alto, CA, United States  
Dzau, Victor J., Los Altos Hills, CA, United States  
Gibbons, Gary H., Palo Alto, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 5891459 19990406  
AI US 1995-556035 19951109 (8)  
RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-76312,  
filed on 11 Jun 1993, now patented, Pat. No. US 5428070  
DT Utility  
LN.CNT 1730  
INCL INCLM: 424/439.000  
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
NCL NCLM: 424/439.000  
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
IC [6]  
ICM: A23L001-305  
ICS: A61K009-00; A61K031-195  
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;  
514/564; 514/565; 424/439; 424/441  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L6 ANSWER 1 OF 1 USPATFULL

TI Enhancement of vascular function by modulation of endogenous  
nitric oxide production or activity

SUMM . . . combination with L-lysine, particularly further supplemented  
with GRAS substances which enhance the effectiveness of the active  
agents, as a dietary **supplement** will increase NO elaboration  
and thereby diminish the effects of atherogenesis. Other techniques to  
enhance NO or secondary messenger availability. . .

DRWD FIGS. 2A, 2B, and 2C are nephelometric scans of the effect of  
L-arginine  
diet **supplement** on platelet reactivity as evidenced by  
platelet aggregation initiated by adenosine diphosphate. (See Ex. 2) A)  
aggregation of platelets from. . .

DRWD FIG. 3 is a bar diagram comparing the effect of L-arginine diet  
**supplement** on cell binding to aortic endothelium of  
hypercholesterolemic animals. (See Ex. 4)

DETD . . . amino acids, in combination, or as a precursor to L-arginine,  
e. g. a monomer or a polypeptide, as a dietary **supplement**. The  
amino acid(s) are administered as any physiologically acceptable salt,  
such as the hydrochloride salt, glutamate salt, etc. They can. . .

DETD . . . calcium (250-1000 mg per daily dose). Furthermore, agents  
known  
to protect NO from degradation, such as antioxidants (e.g. cysteine or  
**N-acetyl cysteine** 200-1000 mg/d Vitamin C  
(250-2000 mg daily dose), (coenzyme Q 25-90 mg daily dose, glutathione  
50-250 mg daily dose), Vitamin. . . formulations of R and/or K, or R  
and/or K-containing peptides. Alternatively, one may include the active  
agent in a nutritional **supplement**, where other additives may  
include vitamins, amino acids, or the like, where the subject active  
agent will be at least. . .

DETD . . . candies, sugar substitutes, soft drinks, and the like. Of  
particular interest is the incorporation of R and/or K as a  
**supplement** in a food, such as a health bar, e.g. granola, other  
grains, fruit bars, such as a date bar, fig. . .

DETD . . . studies, the extent of the thoracic aorta involved by lesions  
was examined. In hypercholesterolemic rabbits receiving vehicle (n=6)  
or  
L-arginine **supplement** (n=6), thoracic aortae (from left  
subclavian artery to diaphragm) were harvested after ten weeks of  
treatment, bisected longitudinally, and stained. . .

CLM What is claimed is:  
. . . of the vascular system of a human host by enhancing endothelial NO,  
said method comprising: administering orally as a dietary  
**supplement** to said host in accordance with a predetermined  
regimen a prophylactic dose in an amount sufficient to enhance  
endogenous endothelial. . .  
. . . of the vascular system of a human host by enhancing endothelial NO,  
said method comprising: administering orally as a dietary  
**supplement** to said host in accordance with a predetermined  
regimen a prophylactic dose in an amount sufficient to enhance  
endogenous endothelial. . .  
. . . of the vascular system of a human host by enhancing endothelial NO,  
said method comprising: administering orally as a dietary  
**supplement** to said host in accordance with a predetermined  
regimen a prophylactic dose in an amount sufficient to enhance  
endogenous endothelial. . .

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

Trying 3106016892...Open

Welcome to STN International! Enter x:x  
LOGINID:sssptaul83jxs  
PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 Expanded CAPlus Coverage of US, Japanese, WIPO,  
EPO, and German patents  
NEWS 3 Feb 1 Addition of Machine-Translated Abstracts to CAPlus  
NEWS 4 Feb 2 STEREO BOND SEARCH PROBLEM FIXED WITH STN EXPRESS 5.0C  
NEWS 5 Feb 14 Homology Searching for Nucleotide Sequences in DGENE  
now available!  
NEWS 6 Feb 16 BIOTECHNOBASE NOW ON STN  
NEWS 7 Feb 22 New Database Producer Clusters Now Available on STN  
NEWS 8 Feb 28 Structure Search Limits Increased in REGISTRY,  
ZREGISTRY, and CASREACT  
NEWS 9 Feb 28 Patent Information Now Searchable in CAOLD  
NEWS 10 Mar 1 New IMSDIRECTORY Provides Pharma Company Details  
NEWS 11 Mar 20 INPADOC: PRODUCER WARNING ABOUT DATA DELAYS  
NEWS 12 Mar 22 NEW FEATURES IN INPADOC - RANGE SEARCHING AND NEW  
SDI/UPDATE SEARCH FIELD

NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000  
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)  
FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)  
HIGHEST PATENT NUMBER: US6044489

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

L1 30772 SEA SUPPLEMENT  
L2 30 SEA L1 AND NITRIC OXIDE PRODUCTION  
L3 0 SEA L2 AND SAPONINS  
L4 0 SEA L2 AND GENSING  
L5 25 SEA L2 AND L(W)ARGININE  
L6 1 SEA L2 AND N(W)ACETYL(W)CYSTEINE  
DISPLAY BROWSE

FILE HOME

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)

FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)

HIGHEST PATENT NUMBER: US6044489

CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

>>> Page images are available for patents from 1/1/96. Current <<<  
>>> week patent text is typically loaded by Thursday morning and <<<  
>>> page images are available for display by the end of the day. <<<  
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<  
>>> is included in file records. A thesaurus is available for the <<<  
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<  
>>> fields. This thesaurus includes catchword terms from the <<<  
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<  
>>> available for the WIPO International Patent Classification <<<  
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<  
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<  
>>> the /IC5 and /IC fields include the corresponding catchword <<<  
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s L2 and folic acid

3045 FOLIC  
486900 ACID  
3007 FOLIC ACID  
(FOLIC(W)ACID)  
L7 1 L2 AND FOLIC ACID

=> display browse

ENTER (L7) OR L#:L7

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L7 ANSWER 1 OF 1 USPATFULL  
AN 1999:56501 USPATFULL  
TI Method of modulating microcirculation  
IN Schneider, Heinz, Cordast, Switzerland  
Thurman, Ronald G., Chapel Hill, NC, United States  
PA Novartis Nutrition AG, Berne, Switzerland (non-U.S. corporation)  
PI US 5902829 19990511



WO 9636327 19961121  
 AI US 1998-952806 19980126 (8)  
 WO 1996-EP2124 19960517  
 19980126 PCT 371 date  
 19980126 PCT 102(e) date  
 PRAI GB 1995-10037 19950518  
 DT Utility  
 LN.CNT 634  
 INCL INCLM: 514/565.000  
 INCLS: 514/045.000  
 NCL NCLM: 514/565.000  
 NCLS: 514/045.000  
 IC [6]  
 ICM: A61K031-195  
 ICS: A61K031-70  
 EXF 514/45; 514/565  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L7 ANSWER 1 OF 1 USPATFULL

SUMM Endogenous **nitric oxide** production can  
 also increase blood flow by reducing the number of blood elements  
 adhering to the lumen of the vessel. In. . .  
 SUMM Examples of vitamins suitable for incorporation into the medicament of  
 the invention include Vitamin A, Vitamin D, Vitamin K, **folic**  
**acid**, thiamin, riboflavin, Vitamin B.sub.6, Vitamin B.sub.12,  
 niacin, biotin and panthotenic acid in pharmaceutically acceptable  
 form.  
 SUMM The medicament or formulation is primarily intended for use as a  
 dietary  
**supplement**. In such a case, the amount of energy supplied by it  
 should not be too excessive, in order not to unnecessarily suppress the  
 patients appetite. The **supplement** should conveniently comprise  
 energy sources in an amount supplying from 600 to 1500 Kcal/day. The  
 contribution of the nitrogen source, . . .

DETD	. . . diet	0.10
Zinc	mg/kg diet	12.00
The vitamin mixture comprises per kg diet:		
A.sup.(1)	4000.00	IU
D.sup.(2)	1000.00	IU
E.sup.(3)	30.00	IU
K.sub.1	50.00	.mu.g
Choline	1000.00	mg
<b>Folic acid</b>	1.00	mg
Niacin	20.00	mg
Pantothenate (calcium)		
	8.00	mg
Riboflavin	3.00	mg
Thiamin	4.00	mg
Vitamin B.sub.6	6.00	mg
Vitamin B.sub.12	50.00	.mu.g

.sup.(1) Vitamin A: . . .  
 ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:fi8ull

'FI8ULL' IS NOT VALID HERE

If you enter "BRIEF", you will see a short review of your session  
 history. If you enter "FULL", you will see a complete review of your

session history.  
ENTER (BRIEF) OR FULL:display his

'DISPLAY HIS' IS NOT VALID HERE  
If you enter "BRIEF", you will see a short review of your session history. If you enter "FULL", you will see a complete review of your session history.  
ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

L1	30772 SEA SUPPLEMENT
L2	30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3	0 SEA L2 AND SAPONINS
L4	0 SEA L2 AND GENSING
L5	25 SEA L2 AND L(W)ARGININE
L6	1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
	DISPLAY BROWSE
L7	1 SEA L2 AND FOLIC ACID
	DISPLAY BROWSE

FILE HOME

FILE USPATFULL  
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)  
FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)  
HIGHEST PATENT NUMBER: US6044489  
CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

>>> Page images are available for patents from 1/1/96. Current <<<  
>>> week patent text is typically loaded by Thursday morning and <<<  
>>> page images are available for display by the end of the day. <<<  
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<  
>>> is included in file records. A thesaurus is available for the <<<  
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<  
>>> fields. This thesaurus includes catchword terms from the <<<  
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<  
>>> available for the WIPO International Patent Classification <<<  
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<  
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<  
>>> the /IC5 and /IC fields include the corresponding catchword <<<  
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD:n

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:n

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.13	20.28

FILE 'CAPLUS' ENTERED AT 17:20:40 ON 03 APR 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 3 Apr 2000 VOL 132 ISS 15  
FILE LAST UPDATED: 2 Apr 2000 (20000402/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

=> s nitric oxide production

```
      89184 NITRIC
     1023142 OXIDE
     278800 PRODUCTION
L8      1039 NITRIC OXIDE PRODUCTION
        (NITRIC(W) OXIDE(W) PRODUCTION)
```

=> s L8 and folic acid

```
      7596 FOLIC
     2409206 ACID
     7518 FOLIC ACID
        (FOLIC(W)ACID)
L9      2 L8 AND FOLIC ACID
```

=> display browse

ENTER (L9) OR L#:L9

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1-2

```
L9  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2000 ACS
AN  1999:819237  CAPLUS
DN  132:35188
TI  Enhancement of exercise performance by augmenting endogenous
    nitric oxide production or activity
IN  Cooke, John P.; Maxwell, Andrew J.
PA  Board of Trustees of the Leland Stanford Junior University, USA
```

```

L1      30772 SEA SUPPLEMENT
L2      30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3      0 SEA L2 AND SAPONINS
L4      0 SEA L2 AND GENSING
L5      25 SEA L2 AND L(W)ARGININE
L6      1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
        DISPLAY BROWSE
L7      1 SEA L2 AND FOLIC ACID
        DISPLAY BROWSE

```

FILE HOME

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)

FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)

HIGHEST PATENT NUMBER: US6044489

CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

```

>>> Page images are available for patents from 1/1/96. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

```

```

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD:n

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9966921	A1	19991229	WO 1999-US12022	19990528
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1998-103340		19980623		

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS

AN 1999:231162 CAPLUS

DN 130:251680

TI Enhancement of vascular function by modulation of endogenous  
**nitric oxide production** or activity

IN Cooke, John P.; Dzau, Victor J.; Gibbons, Gary H.

PA The Board of Trustees of the Leland Stanford Junior University, USA

SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 336,159, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5891459	A	19990406	US 1995-556035	19951109
	US 5428070	A	19950627	US 1993-76312	19930611
	US 5852058	A	19981222	US 1996-695792	19960812
	WO 9716983	A1	19970515	WO 1996-US17241	19961024
	W:	JP			
	RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,			
SE	EP 871376	A1	19981021	EP 1996-938656	19961024
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	US 5861168	A	19990119	US 1996-764919	19961216
	US 5945452	A	19990831	US 1997-796298	19970207
PRAI	US 1993-76312		19930611		
	US 1994-336159		19941108		
	US 1995-556035		19951109		
	US 1996-695792		19960812		
	WO 1996-US17241		19961024		

DETD . . . amino acids, in combination, or as a precursor to L-arginine, e. g. a monomer or a polypeptide, as a dietary **supplement**. The amino acid(s) **is** administered as any physiologically acceptable salt, such as the hydrochloride salt, glutamate salt, etc. They can. . .

DETD . . . calcium (250-1000 mg per daily dose). Furthermore, agents known to protect NO from degradation, such as antioxidants (e.g. cysteine or **N-acetyl cysteine** 200-1000 mg/d Vitamin C (250-2000 mg daily dose), (coenzyme Q 25-90 mg daily dose, glutathione 50-250 mg daily dose), Vitamin. . . formulations of R and/or K, or R and/or K-containing peptides. Alternatively, one may include the active agent in a nutritional **supplement**, where other additives may include vitamins, amino acids, or the like, where the subject active agent will be at least. . .

DETD . . . candies, sugar substitutes, soft drinks, and the like. Of particular interest is the incorporation of R and/or K as a **supplement** in a food, such as a health bar, e.g. granola, other grains, fruit bars, such as a date bar, fig. . .

DETD . . . studies, the extent of the thoracic aorta involved by lesions was examined. In hypercholesterolemic rabbits receiving vehicle (n=6) or L-arginine **supplement** (n=6), thoracic aortae (from left subclavian artery to diaphragm) were harvested after ten weeks of treatment, bisected longitudinally, and stained. . .

CLM What is claimed is:

. . . of the vascular system of a human host by enhancing endothelial NO, said method comprising: administering orally as a dietary **supplement** to said host in accordance with a predetermined regimen a prophylactic dose in an amount sufficient to enhance endogenous endothelial. . .

. . . of the vascular system of a human host by enhancing endothelial NO, said method comprising: administering orally as a dietary **supplement** to said host in accordance with a predetermined regimen a prophylactic dose in an amount sufficient to enhance endogenous endothelial. . .

. . . of the vascular system of a human host by enhancing endothelial NO, said method comprising: administering orally as a dietary **supplement** to said host in accordance with a predetermined regimen a prophylactic dose in an amount sufficient to enhance endogenous endothelial. . .

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:end

=> display his

ENTER (BRIEF) OR FULL:full

ENTER (L1-), L#, OR ?:L1-

(FILE 'HOME' ENTERED AT 17:09:59 ON 03 APR 2000)

FILE 'USPATFULL' ENTERED AT 17:10:20 ON 03 APR 2000

```
L1      30772 SEA SUPPLEMENT
L2      30 SEA L1 AND NITRIC OXIDE PRODUCTION
L3      0 SEA L2 AND SAPONINS
L4      0 SEA L2 AND GENSING
L5      25 SEA L2 AND L(W)ARGININE
L6      1 SEA L2 AND N(W)ACETYL(W)CYSTEINE
        DISPLAY BROWSE
```

FILE HOME

his file contains CAS Registry Numbers for easy and accurate substance identification.

=> s supplement

L1 30772 SUPPLEMENT

=> s L1 and nitric oxide production

49710 NITRIC  
348134 OXIDE  
532819 PRODUCTION  
207 NITRIC OXIDE PRODUCTION  
(NITRIC(W) OXIDE(W) PRODUCTION)

L2 30 L1 AND NITRIC OXIDE PRODUCTION

=> s L2 and saponins

1085 SAPONINS  
L3 0 L2 AND SAPONINS

=> s L2 and gensing

2 GENSING  
L4 0 L2 AND GENSING

=> s L2 and l(w)arginine

611177 L  
19592 ARGININE  
3493 L(W) ARGININE  
L5 25 L2 AND L(W) ARGININE

=> s L2 and N(w)acetyl(w)cysteine

773027 N  
66709 ACETYL  
17143 CYSTEINE  
398 N(W) ACETYL(W) CYSTEINE  
L6 1 L2 AND N(W) ACETYL(W) CYSTEINE

=> display browse

ENTER (L6) OR L#:L6

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL  
AN 1999:43208 USPATFULL  
TI Enhancement of vascular function by modulation of endogenous  
nitric oxide production or activity  
IN Cooke, John P., Palo Alto, CA, United States  
Dzau, Victor J., Los Altos Hills, CA, United States  
Gibbons, Gary H., Palo Alto, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 5891459 19990406  
AI US 1995-556035 19951109 (8)

FILE USPATFULL  
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Mar 2000 (20000328/PD)  
FILE LAST UPDATED: 28 Mar 2000 (20000328/ED)  
HIGHEST PATENT NUMBER: US6044489  
CA INDEXING IS CURRENT THROUGH 28 Mar 2000 (20000328/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Mar 2000 (20000328/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 1999  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Nov 1999

>>> Page images are available for patents from 1/1/96. Current <<<  
>>> week patent text is typically loaded by Thursday morning and <<<  
>>> page images are available for display by the end of the day. <<<  
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<  
>>> is included in file records. A thesaurus is available for the <<<  
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<  
>>> fields. This thesaurus includes catchword terms from the <<<  
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<  
>>> available for the WIPO International Patent Classification <<<  
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<  
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<  
>>> the /IC5 and /IC fields include the corresponding catchword <<<  
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s L2 and folic acid

3045 FOLIC  
486900 ACID  
3007 FOLIC ACID  
(FOLIC(W)ACID)  
L7 1 L2 AND FOLIC ACID

=> display browse

ENTER (L7) OR L#:L7

ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L7 ANSWER 1 OF 1 USPATFULL  
AN 1999:56501 USPATFULL  
TI Method of modulating microcirculation  
IN Schneider, Heinz, Cordast, Switzerland  
Thurman, Ronald G., Chapel Hill, NC, United States  
PA Novartis Nutrition AG, Berne, Switzerland (non-U.S. corporation)  
PI US 5902829 19990511  
WO 9636327 19961121  
AI US 1998-952806 19980126 (8)  
WO 1996-EP2124 19960517  
19980126 PCT 371 date  
19980126 PCT 102(e) date  
PRAI GB 1995-10037 19950518  
DT Utility  
LN.CNT 634  
INCL INCLM: 514/565.000  
INCLS: 514/045.000  
NCL NCLM: 514/565.000  
NCLS: 514/045.000  
IC [6]  
ICM: A61K031-195  
ICS: A61K031-70



RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-76312,  
filed on 11 Jun 1993, now patented, Pat. No. US 5428070  
DT Utility  
LN.CNT 1730  
INCL INCLM: 424/439.000  
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
NCL NCLM: 424/439.000  
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
IC [6]  
ICM: A23L001-305  
ICS: A61K009-00; A61K031-195  
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;  
514/564; 514/565; 424/439; 424/441  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1

L6 ANSWER 1 OF 1 USPATFULL  
AN 1999:43208 USPATFULL  
TI Enhancement of vascular function by modulation of endogenous  
**nitric oxide production** or activity  
IN Cooke, John P., Palo Alto, CA, United States  
Dzau, Victor J., Los Altos Hills, CA, United States  
Gibbons, Gary H., Palo Alto, CA, United States  
PA The Board of Trustees of the Leland Stanford Junior University,  
Stanford, CA, United States (U.S. corporation)  
PI US 5891459 19990406  
AI US 1995-556035 19951109 (8)  
RLI Continuation-in-part of Ser. No. US 1994-336159, filed on 8 Nov 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-76312,  
filed on 11 Jun 1993, now patented, Pat. No. US 5428070  
DT Utility  
LN.CNT 1730  
INCL INCLM: 424/439.000  
INCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
NCL NCLM: 424/439.000  
NCLS: 424/441.000; 426/648.000; 426/656.000; 514/564.000; 514/565.000  
IC [6]  
ICM: A23L001-305  
ICS: A61K009-00; A61K031-195  
EXF 930/290; 530/358; 426/648; 426/656; 426/657; 514/310; 514/20; 514/557;  
514/564; 514/565; 424/439; 424/441  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ENTER (DIS), ANSWER NUMBERS, FORMATS, OR END:1, kwic

L6 ANSWER 1 OF 1 USPATFULL  
TI Enhancement of vascular function by modulation of endogenous  
**nitric oxide production** or activity  
SUMM . . . combination with L-lysine, particularly further supplemented  
with GRAS substances which enhance the effectiveness of the active  
agents, as a dietary **supplement** will increase NO elaboration  
and thereby diminish the effects of atherogenesis. Other techniques to  
enhance NO or secondary messenger availability. . .  
DRWD FIGS. 2A, 2B, and 2C are nephelometric scans of the effect of  
L-arginine  
diet **supplement** on platelet reactivity as evidenced by  
platelet aggregation initiated by adenosine diphosphate. (See Ex. 2) A)  
aggregation of platelets from. . .  
DRWD FIG. 3 is a bar diagram comparing the effect of L-arginine diet  
**supplement** on cell binding to aortic endothelium of  
hypercholesterolemic animals. (See Ex. 4)